These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
316 related articles for article (PubMed ID: 29451965)
21. Aflibercept for Gastrointestinal Bleeding in Hereditary Hemorrhagic Telangiectasia: A Case Report. Villanueva B; Iriarte A; Torres-Iglesias R; Muñoz Bolaño M; Cerdà P; Riera-Mestre A Medicina (Kaunas); 2023 Aug; 59(9):. PubMed ID: 37763652 [TBL] [Abstract][Full Text] [Related]
22. Effect of Topical Intranasal Therapy on Epistaxis Frequency in Patients With Hereditary Hemorrhagic Telangiectasia: A Randomized Clinical Trial. Whitehead KJ; Sautter NB; McWilliams JP; Chakinala MM; Merlo CA; Johnson MH; James M; Everett EM; Clancy MS; Faughnan ME; Oh SP; Olitsky SE; Pyeritz RE; Gossage JR JAMA; 2016 Sep; 316(9):943-51. PubMed ID: 27599329 [TBL] [Abstract][Full Text] [Related]
23. Intranasal bevacizumab injections improve quality of life in HHT patients. Steineger J; Geirdal AØ; Osnes T; Heimdal KR; Dheyauldeen S Laryngoscope; 2020 May; 130(5):E284-E288. PubMed ID: 31287573 [TBL] [Abstract][Full Text] [Related]
24. Is bevacizumab effective for reducing epistaxis in hereditary hemorrhagic telangiectasia? Chin CJ Laryngoscope; 2017 Feb; 127(2):289-290. PubMed ID: 27796042 [No Abstract] [Full Text] [Related]
25. [Effects of bevacizumab on familial epistaxis caused by hereditary hemorrhagic telangiectasia]. Zhang J; Wang XS; Wang HT Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2021 May; 56(5):436-441. PubMed ID: 34010995 [No Abstract] [Full Text] [Related]
26. Medical Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia: A Meta-analysis. Hsu YP; Hsu CW; Bai CH; Cheng SW; Chen C Otolaryngol Head Neck Surg; 2019 Jan; 160(1):22-35. PubMed ID: 30200816 [TBL] [Abstract][Full Text] [Related]
27. The effect of bevacizumab (Avastin) treatment on epistaxis in hereditary hemorrhagic telangiectasia. Simonds J; Miller F; Mandel J; Davidson TM Laryngoscope; 2009 May; 119(5):988-92. PubMed ID: 19194865 [TBL] [Abstract][Full Text] [Related]
28. Intranasal bevacizumab in the treatment of HHT -related epistaxis: a systematic review. Stokes P; Rimmer J Rhinology; 2018 Mar; 56(1):3-10. PubMed ID: 29166422 [TBL] [Abstract][Full Text] [Related]
29. Systemic Antiangiogenic Therapies for Bleeding in Hereditary Hemorrhagic Telangiectasia: A Practical, Evidence-Based Guide for Clinicians. Al-Samkari H Semin Thromb Hemost; 2022 Jul; 48(5):514-528. PubMed ID: 35226946 [TBL] [Abstract][Full Text] [Related]
30. ELLIPSE Study: a Phase 1 study evaluating the tolerance of bevacizumab nasal spray in the treatment of epistaxis in hereditary hemorrhagic telangiectasia. Dupuis-Girod S; Ambrun A; Decullier E; Samson G; Roux A; Fargeton AE; Rioufol C; Schwiertz V; Disant F; Chapuis F; Donazzolo Y; Paintaud G; Edery P; Faure F MAbs; 2014; 6(3):794-9. PubMed ID: 24481211 [TBL] [Abstract][Full Text] [Related]
31. Intranasal submucosal bevacizumab for epistaxis in hereditary hemorrhagic telangiectasia: a double-blind, randomized, placebo-controlled trial. Riss D; Burian M; Wolf A; Kranebitter V; Kaider A; Arnoldner C Head Neck; 2015 Jun; 37(6):783-7. PubMed ID: 24595923 [TBL] [Abstract][Full Text] [Related]
32. Selective effects of oral antiangiogenic tyrosine kinase inhibitors on an animal model of hereditary hemorrhagic telangiectasia. Kim YH; Kim MJ; Choe SW; Sprecher D; Lee YJ; P Oh S J Thromb Haemost; 2017 Jun; 15(6):1095-1102. PubMed ID: 28339142 [TBL] [Abstract][Full Text] [Related]
34. Does severe bleeding in HHT patients respond to intravenous bevacizumab? Review of the literature and case series. Rosenberg T; Fialla AD; Kjeldsen J; Kjeldsen AD Rhinology; 2019 Aug; 57(4):242-251. PubMed ID: 30907391 [TBL] [Abstract][Full Text] [Related]
35. The treatment of recurrent epistaxis due to hereditary haemorrhagic telangiectasia with intranasal bevacizumab. Alderman C; Corlett J; Cullis J Br J Haematol; 2013 Aug; 162(4):547-8. PubMed ID: 23672440 [No Abstract] [Full Text] [Related]
36. Long-term therapy with bevacizumab in hereditary hemorrhagic telangiectasia. Brinkerhoff BT; Poetker DM; Choong NW N Engl J Med; 2011 Feb; 364(7):688-9. PubMed ID: 21323562 [No Abstract] [Full Text] [Related]
37. An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study. Al-Samkari H; Kasthuri RS; Parambil JG; Albitar HA; Almodallal YA; Vázquez C; Serra MM; Dupuis-Girod S; Wilsen CB; McWilliams JP; Fountain EH; Gossage JR; Weiss CR; Latif MA; Issachar A; Mei-Zahav M; Meek ME; Conrad M; Rodriguez-Lopez J; Kuter DJ; Iyer VN Haematologica; 2021 Aug; 106(8):2161-2169. PubMed ID: 32675221 [TBL] [Abstract][Full Text] [Related]
38. Systemic therapy with bevacizumab in patients with hereditary hemorrhagic telangiectasia (HHT). Chavan A; Schumann-Binarsch S; Luthe L; Nickau B; Elsässer A; Kühnel T; Geisthoff U; Köhne H Vasa; 2013 Mar; 42(2):106-10. PubMed ID: 23485837 [TBL] [Abstract][Full Text] [Related]
39. Duration of effectiveness of coblation for recurrent epistaxis in hereditary hemorrhagic telangiectasia. Feller CN; Adams JA; Friedland DR; Poetker DM Am J Otolaryngol; 2022; 43(3):103409. PubMed ID: 35216850 [TBL] [Abstract][Full Text] [Related]
40. Endoscopic-guided coblation treatment of nasal telangiectasias in hereditary hemorrhagic telangiectasia: "How I do it". Poetker DM Am J Rhinol Allergy; 2017 May; 31(3):205-206. PubMed ID: 28490409 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]